1-3 of 3
Bart Scott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD
Journal: Blood
Blood (2009) 114 (22): 3905.
https://doi.org/10.1182/blood.V114.22.3905.3905
Published: 2009
Journal Articles

NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)

Daniella M. B. Kerbauy, Vladimir Lesnikov, Nissa Abbasi, Sudeshna Seal, Bart Scott, H. Joachim Deeg
Journal: Blood
Blood (2005) 106 (12): 3917–3925.
https://doi.org/10.1182/blood-2005-04-1424
Published: 2005
Journal Articles

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Frederic Baron, MD, PhD, David Maloney, MD, PhD, Bart Scott, MD, H. Joachim Deeg, MD, Rainert Storb, MD
Journal: Blood
Blood (2005) 106 (11): 705.
https://doi.org/10.1182/blood.V106.11.705.705
Published: 2005